Table 2.
DRUG off-label uses ranked by inspire information component (IC) that were discussed more than average (inspire count) in the related disease support group; claims count is the number of patients in Truven data with a record of the drug starting within the course of the corresponding disease. Claims IC is the calculated information component based on claims records. NIC is normalized information component
| Drug | Disease | Inspire count | Inspire IC (NIC) | Claims count | Claims IC (NIC) |
|---|---|---|---|---|---|
| Temodar | Skin cancer | 10 | 6.03 (0.56) | 1062 | −2.60 (−0.20) |
| Oxaliplatin | Stomach cancer | 12 | 4.88 (0.38) | 49 | 2.98 (0.17) |
| Pazopanib | Thyroid cancer | 21 | 4.36 (0.36) | 120 | 0.24 (0.01) |
| Mutamycin | Bladder cancer | 653 | 4.22 (0.63) | 169 | 3.49 (0.23) |
| Cisplatin | Head and neck cancer | 264 | 2.33 (0.29) | 34 | 2.66 (0.15) |
| Platinol | Cervical cancer | 399 | 2.31 (0.31) | 28 | 2.70 (0.15) |
| Pazopanib | Ovarian cancer | 83 | 0.39 (0.04) | 125 | 1.02 (0.06) |
| Erbitux | Lung cancer | 271 | 0.35 (0.04) | 73 | 2.49 (0.15) |
| Carboplatin | Prostate cancer | 49 | −0.14 (−0.02) | 42 | −1.49 (−0.08) |
| Avastin | Breast cancer | 562 | −0.82 (−0.12) | 173 | −0.34 (−0.02) |
| Paclitaxel | Colorectal cancer | 9 | −3.69 (−0.29) | 32 | −0.35 (−0.02) |